Immunogen Inc. (IMGN) Posts Q1 Loss of $0.22; Reaffirms Guidance
More News related to IMGN
- ImmunoGen, Inc. Announces Clinical Data Presentations on Three TAP Compounds at Upcoming ASH Annual Meeting and Exposition
- ImmunoGen (IMGN) To License TAP Technology to Amgen Inc.
- ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company's TAP Technology
- ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma
- Trading Overview for Poniard Pharmaceuticals Inc. Issued by Beacon Equity
More News related to Earnings
- Spectrum Pharma (SPPI) Files $250M Mixed Shelf
- Bank of Kentucky Financial (BKYF) Files $50M Mixed Shelf
- Nanophase Tech. (NANX) Files 847K Common Shelf for Selling Shareholders
- Altra Holdings (AIMC) Closes $210M Senior Notes Offering; Enters Into Revolving Credit Facility; Subsidiary Tenders $167.9M of Senior Notes
- Sigma Designs (SIGM) Files 3.93M Share Shelf for Common Stock
Immunogen Inc. (NASDAQ: IMGN) reports Q1 loss of $0.22, cents better than the analyst estimate of ($0.20). Revenue for the quarter was $3.10 million, which compares to the estimate of $4.54 million.
Reaffirms guidance.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
